((自动化翻译由路透提供，请见免责声明 ))
路透社1月22日 - 雅培实验室 周三 预测年度利润与华尔街预期一致，因为该公司预计医疗技术相关程序的增加将促进对其设备（包括葡萄糖监测产品）的需求。
雅培的FreeStyle Libre等连续血糖监测仪和DexCom 等竞争对手的销售额因糖尿病护理意识的提高、保险覆盖面的扩大以及对无需扎手指的设备的偏好而得到提升。
雅培预计2025年调整后每股利润为5.05美元至5.25美元，而 分析师的平均预期利润为5.16美元。
根据伦敦证券交易集团（LSEG）汇编的估计数据，该公司经调整后的季度利润为每股1.34美元 ，符合分析师的平均预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.